freespincoinmasterhaktuts| Kangfang Biotech's share price plummeted by 28.2%: AK112 was approved for marketing, clinical data was questioned

News summary

Kangfang Biotech announced the approval of AK112 after its share price collapsed, but the market is skeptical about the clinical data compared with Columbotai.

Newsletter text

Kangfang Biotech's share price fell sharply today, frustrating investor sentiment

This morning, Kangfang Biotech (09926freespincoinmasterhaktuts.HK）freespincoinmasterhaktutsshare price fell sharply, reaching 28freespincoinmasterhaktuts.2%。Market rumors pointed out that this decline may be related to the company's AK112 Ivocizumab injection clinical trial data failed to meet expectations.

AK112 Ivolumab injection is the second dual antibody drug commercialized by Kangfang Biotech Project. Its trade name is Idarfang. Despite the sharp decline in stock price, Kangfang Biotech's AK112 still receivedfreespincoinmasterhaktutsRecognized by the domestic market. The official website of the State Food and Drug Administration released a message saying that after the priority review and approval process, the AK112 ivocizumab injection applied by Kangfonsano Pharmaceutical Co., Ltd. has been approved for marketing. The drug will be used in conjunction with pemetrexed and carboplatin to treat specific types of non-small cell lung cancer.

Market analysis shows that Kangfang Biotech's AK112 clinical data is not as good as the second-phase data of Collobatic's ADC drug rukangsartuzumab (SKB264). Despite this, some analysts pointed out that the indications for the two are different, and Colenotek's SKB264 is only in the phase II clinical trial stage, while Kangfang Biotech's AK112 has entered the phase III clinical trial.

Although Kangfang Biotech's share price fell sharply, the company has not yet made an official response. Investors should pay close attention to the company's future announcements for more detailed information on AK112 clinical trial data.